Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.

Blood - 1 Mar 2008

Copland Mhairi, Pellicano Francesca, Richmond Linda, Allan Elaine K, Hamilton Ashley, Lee Francis Y, Weinmann Roberto, Holyoake Tessa L

Abstract excerpt

Chronic myeloid leukemia (CML), a hematopoietic stem-cell disorder, cannot be eradicated by conventional chemotherapy or the tyrosine kinase inhibitor imatinib mesylate (IM). To target CML stem/progenitor cells, we investigated BMS-214662, a cytotoxic farnesyltransferase inhibitor, previously rep...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD34
Share to Benzodiazepines
Share to Blast Crisis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Caspase 3

Share to Dasatinib

Share to Drug Screening Assays, Antitumor

Share to Farnesyltranstransferase

Share to Philadelphia Chromosome

Source

Identifiers

PMID: 18156496
DOI: 10.1182/blood-2007-09-112573

Genes

BCR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18156496-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.PMID 18156496Read ↗

Characterization of cancer stem cells in chronic myeloid leukaemiaSemantic proximity Read ↗

Chronic Myeloid Leukemia Stem CellsSemantic proximity Read ↗

Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cellsSemantic proximity Read ↗

The pan-Bcl-2 inhibitor obatoclax promotes differentiation and apoptosis of acute myeloid leukemia cellsSemantic proximity Read ↗

HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.Semantic proximity Read ↗

Preferential induction of apoptosis for primary human leukemic stem cells.Semantic proximity Read ↗

The stem cell factor–c-KIT pathway must be inhibited to enable apoptosis induced by BCR–ABL inhibitors in chronic myelogenous leukemia cellsSemantic proximity Read ↗

Critical molecular pathways in cancer stem cells of chronic myeloid leukemia.Semantic proximity Read ↗

p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells.Semantic proximity Read ↗

Inhibition of BCR::ABL1 tyrosine kinase activity Aids in the Generation of Stable Chronic Myeloid Leukemia Induced Pluripotent Stem CellsSemantic proximity Read ↗

Synergistic Targeting of AML Stem/Progenitor Cells With IAP Antagonist Birinapant and Demethylating AgentsSemantic proximity Read ↗

Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.